O’ZBEKISTON RESPUBLIKASI FARMATSEVTIKA BOZORIDA BUYRAK-TOSH KASALLIKLARIDA ISHLATILADIGAN DORI VOSITALARINING ASSORTIMENT TAXLILI

Admin bo'lib kirish (www.admin.slib.uz)

Tizim sinov (TEST) rejimida ishlamoqda! Murojat uchun @slib_support

Eski talqinga o'tish link

26 март 2025

Asosiy til:O'zbek

O’ZBEKISTON RESPUBLIKASI FARMATSEVTIKA BOZORIDA BUYRAK-TOSH KASALLIKLARIDA ISHLATILADIGAN DORI VOSITALARINING ASSORTIMENT TAXLILI

Fan yo'nalishi:

67e41a4e9c108.pdf

PDF

Eurasian Journal of Medical and Natural Sciences

Maqola chop etish see more

MAQOLA ANNOTATSIYASI

Nefrolitiaz –buyrak va siydik yo‘llarida tosh hosil bo‘lishi bilan kechuvchi kasallik. Tadqiqotda mamlakatimizda buyrak-toshkasalligiga qarshi dori vositalarining tarkibi, miqdori, shakli va narxi tahlil qilindi. So‘nggi to‘rt yilda buyrak-tosh kasalligiga qarshi dorilar tahlil qilinganda, asosan oksalat va urat toshlariga qarshi vositalar ko‘proq qo‘llangani aniqlandi. Xorijiy dorilar ulushi 58,34% dan 42,85% gacha kamaydi, mahalliy ishlab chiqaruvchilarning ulushi 25% dan 28,57% gacha, MDH davlatlarinik esa 16,67% dan 28,57% gacha oshdi. Biroq, umumiy miqdor jihatdan sezilarli o‘zgarish kuzatilmadi. Eng ko‘p ishlatiladigan dori shakllari tabletka va kapsulalar (33,3%) bo‘lib, ularning barchasi xorijiy yoki MDH davlatlarida ishlab chiqarilgan. Mahalliy ishlab chiqaruvchilar orasida ushbu dori shakllari mavjud emas. Shuningdek, kukun, granula, sirop va inyeksion eritmalar (8,33%) ham qo‘llaniladi. Import qilingan dorilarning tannarxi yuqori ekani qayd etildi. Tadqiqotning maqsadi –samarali tabletka shaklidagi dori ishlab chiqarish texnologiyasini o‘rganish va farmatsevtika sohasidagi mavjud bo‘shliqni bartaraf etishdir

MUALIFLAR

Teglar

# tuzlar# Buyrak-tosh kasalligi# natriy sitrat# kaliy gidrokarbonat# limon kislotali# siydik kislotasi# metabolik kasallik

Maqolani baholang

0

0 ta

Maqola idintifikatorlari

ROI:

https://eroi.uz/11.0201/A0325-0195

DOI:

Mavjud emas

Foydalanilgan adabiyotlar

1.Sofia, N. H., & Walter, T. M. (2016). Prevalence andrisk factors of kidney stone.Global Journal for Research Analysis.2.Ferraro, P. M., Ferraro, P. M., Ferraro, P. M., Robertson, W. G., Robertson, W. G., Robertson, W. G., Unwin, R., Unwin, R., & Unwin, R. (2007). Renal stone disease.Medicine. https://doi.org/10.1016/J.MPMED.2015.05.0032.Zanni, G. R. (2009). Kidney stones: painful and common--but preventable. The Consultant Pharmacist : The Journal of the American Society of Consultant Pharmacists. https://doi.org/10.4140/TCP.N.2009.3383.Peerapen P, Thongboonkerd V. Kidney Stone Prevention. Adv Nutr. 2023 May;14(3):555-569. doi: 0.1016/j.advnut.2023.03.002. Epub 2023 Mar 9. PMID: 36906146; PMCID: PMC10201681.4.Kartha G, Calle JC, Marchini GS, Monga M. Impact of stone disease: chronic kidney disease and quality of life. Urol Clin North Am. 2013 Feb;40(1):135-47. doi: 10.1016/j.ucl.2012.09.004. Epub 2012 Oct 23. PMID: 23177641.5.Wang Z, Zhang Y, Zhang J, Deng Q, Liang H. Recent advances on the mechanisms of kidney stone formation (Review). Int J Mol Med. 2021 Aug;48(2):149. doi: 10.3892/ijmm.2021.4982. Epub 2021 Jun PMID: 34132361; PMCID: PMC8208620.6.Konstantinova OV, Yanenko EK. [EXPERIENCE OF USE OF BLEMAREN® IN THE TREATMENT OF PATIENTS IN URIC ACID AND CALCIUM OXALATE UROLITHIASIS]. Urologiia. 2015 Sep-Oct;(5):22-4, Russian. PMID: 26859932.7.Goswami, P. K. (2014). Urolithiasis: An Overview.International Journal of Pharmaceutical & Biological Archive.8.Tyagi, S. (2012). Review on Kidney Stones.Journal of Biomedical and Pharmaceutical Research.